NO20073271L - Nye pyridotienopyrimidinderivater - Google Patents

Nye pyridotienopyrimidinderivater

Info

Publication number
NO20073271L
NO20073271L NO20073271A NO20073271A NO20073271L NO 20073271 L NO20073271 L NO 20073271L NO 20073271 A NO20073271 A NO 20073271A NO 20073271 A NO20073271 A NO 20073271A NO 20073271 L NO20073271 L NO 20073271L
Authority
NO
Norway
Prior art keywords
groups
group
alkyl
hydrogen atoms
independently selected
Prior art date
Application number
NO20073271A
Other languages
English (en)
Inventor
Jordi Gracia Ferrer
Lluis Miquel Pages Santacana
Joan Taltavull Moll
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of NO20073271L publication Critical patent/NO20073271L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Anvendelse av etpyrido[3',2':4,5]tieno[3,2-d]pyrimidinderivat med formel (I). hvori. n er et helt tall valgt fra 0 eller 1,. Rog Rer uavhengig valgt fra hydrogenatomer og C.alkylgrupper, Rrepresenterer en gruppe valgt fra alkyl, amino, monoalkylamino, dialkylamino, aryl, heteroaryl og mettede N-inneholdende heterocyklylgrupper bundet via nitrogenatomet til pyridinringen, og alle er de valgfritt substituert med en eller flere substituenter valgt fra gruppen bestående av halogenatomer og alkyl, alkoksyalkyl, arylalkyl, ROCO-, alkoksy, RRN-CO-, -CN, -CF,. -, -SRog -S0NH, hvoriog Rer uavhengig valgt fra hydrogenatomer og Calkylgrupper, Rog Rer uavhengig valgt fra gruppen bestående av hydrogenatomer,alkylgrupper og grupper med formel (II): hvori p og q er hele tall valgt fra 1, 2 og 3; A er enten en direkte binding eller en gruppe valgt fra -CONR, - NRCO-, -O-, -COO-, -OCO-, -NRCOO-, -OCONR, -NRCONR, -S-, -SO-, -S0-, -COS- og -SCO-; og Ger en gruppe valgt fra aryl, heteroaryl eller heterocyklyl; hvori alkylgruppene og gruppen Ger valgfritt substituert med en eller flere substituenter valgt fra gruppen bestående av halogenatomer og alkyl, alkoksyalkyl, arylalkyl, ROCO-, hydroksy, alkoksy, okso, RRCO-, -CN, - CF, -NRR, -SRog -S0NHgrupper; hvori gruppene Rtil Rer uavhengig valgt fra hydrogenatomer og C_alkylgrupper; og de farmasøytisk akseptable salter og N-oksider derav; i fremstillingen av et medikament for behandling eller forhindring av en patologisk tilstand eller sykdom som er mottagelig for bedring ved inhibisjon av fosfodiesterase 4.
NO20073271A 2004-11-30 2007-06-26 Nye pyridotienopyrimidinderivater NO20073271L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200402877A ES2259892B1 (es) 2004-11-30 2004-11-30 Nuevos derivados de piridotienopirimidina.
PCT/EP2005/012773 WO2006058723A1 (en) 2004-11-30 2005-11-30 New pyridothienopyrimidine derivatives

Publications (1)

Publication Number Publication Date
NO20073271L true NO20073271L (no) 2007-06-26

Family

ID=35064809

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073271A NO20073271L (no) 2004-11-30 2007-06-26 Nye pyridotienopyrimidinderivater

Country Status (19)

Country Link
US (1) US20080207645A1 (no)
EP (1) EP1819712A1 (no)
JP (1) JP2008521854A (no)
KR (1) KR20070086652A (no)
CN (1) CN101068817A (no)
AR (1) AR052413A1 (no)
AU (1) AU2005311422A1 (no)
BR (1) BRPI0518117A (no)
CA (1) CA2588808A1 (no)
ES (1) ES2259892B1 (no)
IL (1) IL183141A0 (no)
MX (1) MX2007006172A (no)
NO (1) NO20073271L (no)
PE (1) PE20061080A1 (no)
RU (1) RU2007124493A (no)
TW (1) TW200631954A (no)
UY (1) UY29240A1 (no)
WO (1) WO2006058723A1 (no)
ZA (1) ZA200703700B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281251B1 (es) * 2005-07-27 2008-08-16 Laboratorios Almirall S.A. Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina.
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
JP2015512862A (ja) 2011-12-21 2015-04-30 インヴィスタ テクノロジーズ エスアエルエル 安定なエマルジョンを減じるための抽出溶媒制御
CN103242276B (zh) * 2013-05-07 2014-07-16 白银安杰利生化科技有限公司 2,2-二甲基四氢-2h-吡喃-4-羧酸的合成方法
BR112018003417B1 (pt) 2016-06-22 2023-10-24 Vanderbilt University Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA46722A (fr) 2016-11-07 2019-09-11 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
JP7099725B2 (ja) 2016-11-07 2022-07-12 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
US11376254B2 (en) 2017-12-05 2022-07-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
KR20010105399A (ko) * 1999-03-30 2001-11-28 쓰끼하시 다미까따 티에노피리미딘 화합물 및 그의 염, 및 그들의 제조 방법

Also Published As

Publication number Publication date
CN101068817A (zh) 2007-11-07
PE20061080A1 (es) 2006-11-10
ZA200703700B (en) 2008-07-30
ES2259892A1 (es) 2006-10-16
MX2007006172A (es) 2007-07-13
RU2007124493A (ru) 2009-01-10
KR20070086652A (ko) 2007-08-27
WO2006058723A8 (en) 2007-07-12
WO2006058723A1 (en) 2006-06-08
AR052413A1 (es) 2007-03-21
TW200631954A (en) 2006-09-16
ES2259892B1 (es) 2007-11-01
IL183141A0 (en) 2007-09-20
UY29240A1 (es) 2006-02-24
US20080207645A1 (en) 2008-08-28
EP1819712A1 (en) 2007-08-22
CA2588808A1 (en) 2006-06-08
JP2008521854A (ja) 2008-06-26
BRPI0518117A (pt) 2008-11-04
AU2005311422A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
NO20073271L (no) Nye pyridotienopyrimidinderivater
NO20073283L (no) Nye pyridotienopyrimidinderivater
NZ605528A (en) Ip receptor agonist heterocyclic compounds
MY153393A (en) Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors
NO20072115L (no) Farmasoytiske forbindelser
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
NO20084832L (no) Pyrimidinderivater som P13K-inhibitorer
WO2008111441A1 (ja) 医薬組成物
WO2009156861A8 (en) Substituted pyrimidone derivatives
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
WO2009156864A3 (en) Substituted alkyl pyrimidin-4-one derivatives
NO20064089L (no) Kondensert ring 4-oksopyrimidinderivat
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
NZ626068A (en) Multicyclic compounds and methods of use thereof
NO20054952L (no) 2,3,6-trisubstituerte 4-pyrimidonderivater
WO2008114817A1 (ja) 新規なアデニン化合物
NO20065694L (no) Indolderivat med piperidinring
MY144588A (en) Novel coumarin derivative having antitumor activity
WO2009069736A1 (ja) 含窒素化合物
NO20063905L (no) Imidazolo-5-YL-Anilinopyrimidiner som midler for inhibering av celle proliferasjon
NO20072831L (no) Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
WO2008136444A1 (ja) 縮合複素環誘導体
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application